

**In the Claims**

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please cancel claims 18-34 without prejudice or disclaimer.

Please add new claims 42-62 as noted below.

1.-41. (Canceled)

42. An isolated peptide that binds to human mannose binding lectin (MBL), comprising:

i) a CDR3 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619, or

ii) a CDR3 of i) with a conservative substitution therein, wherein the conservatively substituted CDR3 binds to human MBL.

43. The peptide of claim 42, wherein the CDR3 is a heavy chain CDR3.

44. The peptide of claim 42, wherein the peptide comprises a CDR3 region of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.

45. The peptide of claim 42, wherein the peptide comprises a CDR3 region of a monoclonal antibody produced by hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.

46. The peptide of claim 42, wherein the peptide comprises a CDR3 region of a monoclonal antibody produced by hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

47. The peptide of claim 42, wherein the peptide is a monoclonal antibody.
48. The peptide of claim 47, wherein the monoclonal antibody is produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.
49. The peptide of claim 47, wherein the monoclonal antibody is produced by hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.
50. The peptide of claim 47, wherein the monoclonal antibody is produced by hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.
51. The peptide of claim 47, wherein the monoclonal antibody is a humanized monoclonal antibody.
52. The peptide of claim 42, wherein the peptide is an antibody fragment selected from the group consisting of an F(ab')<sub>2</sub> fragment, an Fab fragment, an Fv fragment, and an Fd fragment.
53. The peptide of claim 42, further comprising:
- i) a CDR2 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619, or
  - ii) a CDR2 of i) with a conservative substitution therein, wherein the conservatively substituted CDR2 binds to human MBL.
54. The peptide of claim 53, wherein the CDR2 is a light chain CDR2.
55. The peptide of claim 42, further comprising:

i) a CDR1 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619, or

ii) a CDR1 of i) with a conservative substitution therein, wherein the conservatively substituted CDR1 binds to human MBL.

56. The peptide of claim 55, wherein the CDR1 is a light chain CDR1.

57. The peptide of claim 55, further comprising:

i) a CDR2 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619, or

ii) a CDR2 of i) with a conservative substitution therein, wherein the conservatively substituted CDR2 binds to human MBL.

58. A hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.

59. A hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.

60. A hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

61. A pharmaceutical composition comprising:

i) an effective amount of the peptide of claim 42 for treating an MBL mediated disorder, and ii) a pharmaceutically acceptable carrier.

62. The pharmaceutical composition of claim 61, further comprising a drug for the treatment of an MBL mediated disorder.